These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17348449)

  • 1. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
    Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
    Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
    Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
    Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
    Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
    Stephan C; Meyer HA; Paul EM; Kristiansen G; Loening SA; Lein M; Jung K
    Anticancer Res; 2007; 27(4A):1833-6. PubMed ID: 17649780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
    Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
    Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
    Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
    Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
    Romppanen J; Haapalainen T; Punnonen K; Penttilä I
    Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
    Egawa S; Soh S; Ohori M; Uchida T; Gohji K; Fujii A; Kuwao S; Koshiba K
    Cancer; 1997 Jan; 79(1):90-8. PubMed ID: 8988731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
    de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH
    Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.